Question to the Cabinet Office:

To ask the Minister for the Cabinet Office, what justification is being applied to changes to the Infected Blood Compensation Scheme, where individuals who suffered long-term health harms of interferon treatment are to receive an uplift in compensation from 2017 onwards rather than from when their treatment began.

The Inquiry recommended changes to the infection severity bands to give greater recognition for the suffering caused by interferon treatment. The Government agrees that changes are needed and we have consulted on our proposal to introduce a new infection severity band, referred to as Level 2B, which would increase people’s financial loss and care compensation awards where relevant, to recognise the short-term side-effects that many, but not all, people suffer due to interferon treatment.

The Government proposed that all infected people who have received treatment with interferon will qualify for the proposed Level 2B infection severity band. It will be part of their core compensation award and people will be eligible for it even if they were only able to tolerate interferon treatment for a very short period.

We recognise that some infected people have suffered and continue to suffer debilitating, long-term impacts on their ability to work. We have therefore consulted on a proposal to introduce a new Special Category Mechanism (SCM) Severe Health Condition award which would offer higher awards for financial loss and care based on the enduring impact that people have experienced in relation to their ability to work and their need for care.

The consultation closed on 22 January, and the Government will publish its response within 12 weeks of this closing date.